BOSTON and LONDON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (the “Company”), an oncology biotechnology company…
Findings complement previously announced results in triple-negative breast cancer (TNBC) and prostate cancer models, highlighting Telomir-1's consistent impact on cancer…
Prestigious European Society for Medical Oncology Conference “trials-in-progress” session Pivotal OVATION 3 trial of its DNA-mediated immunotherapy in newly diagnosed…
$50 million drawn down at closing, with access to up to an additional $80 millionStrengthens Company’s financial position; enables initiation…
NEEDHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical…
Presentation will cover two-year clinical efficacy, immunogenicity and safety dataData will be presented at an oral session on October 17,…
- VCN-01 expanded mPDAC data from VIRAGE Phase 2b trial to be presented at ESMO 2025 - - SYN-004 Interim…
Confirmation of 30mg efti as optimal biological dose relevant for Immutep’s oncology pipeline and potential future Biological License Applications (BLA)Registrational…
Sales Highlights (unaudited): Global•Q1 sales AUD$2.0 million up 34% on prior comparative period (pcp) Australia•Q1 sales AUD$1.6 million up 52% on…
THEO-260 is an oncolytic immunotherapy developed for effective targeting of cancer cells and cancer-associated fibroblasts, whilst inducing immune activation in…